MacroGenics, Inc.MGNX
Key ratios
FCF / Sales
-55.5%2025
2024
-48.1%2023
-136.1%
Net margin
-8.3%TTM
2025
-49.9%2024
-44.7%2023
-15.4%
ROA
-17.6%2025
2024
-24.7%2023
-36.3%
ROE
-87.0%2025
2024
-49.9%2023
-6.2%
Revenue growth
-0.3%2025
2024
155.3%2023
-61.3%
Recent news
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program
Track MGNX in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer